help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on August 25, 2005, doi:10.1165/rcmb.2005-0124OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0124OCv1
33/6/531    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, J.
Right arrow Articles by Jeffery, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, J.
Right arrow Articles by Jeffery, P. K.
American Journal of Respiratory Cell and Molecular Biology. Vol. 33, pp. 531-540, 2005
© 2005 American Thoracic Society
DOI: 10.1165/rcmb.2005-0124OC

Localization and Upregulation of Cysteinyl Leukotriene-1 Receptor in Asthmatic Bronchial Mucosa

Jie Zhu, Yu-Sheng Qiu, David J. Figueroa, Venkata Bandi, Helen Galczenski, Kaoru Hamada, Kalpalatha K. Guntupalli, Jilly F. Evans and Peter K. Jeffery

Imperial College London at the Royal Brompton Hospital, London, United Kingdom; Merck & Co., Inc., West Point, Pennsylvania; Baylor College of Medicine, Houston, Texas; and Nara Medical University, Nara, Japan

Correspondence and requests for reprints should be addressed to Professor Peter K. Jeffery, Lung Pathology, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom. E-mail: p.jeffery{at}imperial.ac.uk

We have tested the hypothesis that the CysLT1 receptor is expressed by a variety of bronchial mucosal immune cells and that the numbers of these cells increase in asthma, when stable and in exacerbations. We have applied in situ hybridization and immunohistochemistry to endobronchial biopsy tissue to identify and count inflammatory cells expressing CysLT1 receptor mRNA and protein, respectively, and used double immunohistochemistry to identify the specific cell immunophenotypes expressing the receptor. Double-labeling demonstrated that bronchial mucosal eosinophils, neutrophils, mast cells, macrophages, B-lymphocytes, and plasma cells, but not T-lymphocytes, expressed the CysLT1 receptor. The numbers of CysLT1 receptor mRNA and protein positive inflammatory cells in nonsmoking, nonatopic control subjects without asthma were 13 and 16 mm–2, respectively (median values; n = 15), and were significantly greater in stable asthma (50 and 43 mm–2, respectively; n = 17; P < 0.001). Compared with stable asthma, there were further significant increases in subjects hospitalized for a severe exacerbation of their asthma (mRNA: median = 113 and protein: 156 mm–2; n = 15; P < 0.002). For the combined data of both asthma subgroups, there were strong positive correlations between the increased numbers of CD45+ leukocytes and the greater numbers of cells expressing CysLT1 receptor (mRNA: r = 0.60, P < 0.001; protein: r = 0.73, P < 0.0001). In conclusion, a variety of immunohistologically distinct inflammatory cells express the CysLT1 receptor in the bronchial mucosa and both these and the total number of leukocytes increase in mild stable disease and increase further when there is a severe exacerbation of asthma.

Key Words: asthma • cysteinyl leukotrienes • exacerbation • receptor




This article has been cited by other articles:


Home page
J. Immunol.Home page
E. Gaudreault and J. Gosselin
Leukotriene B4 Potentiates CpG Signaling for Enhanced Cytokine Secretion by Human Leukocytes
J. Immunol., August 15, 2009; 183(4): 2650 - 2658.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. G. Kaditis, E. Alexopoulos, K. Chaidas, G. Ntamagka, A. Karathanasi, I. Tsilioni, T. S. Kiropoulos, E. Zintzaras, and K. Gourgoulianis
Urine Concentrations of Cysteinyl Leukotrienes in Children With Obstructive Sleep-Disordered Breathing
Chest, June 1, 2009; 135(6): 1496 - 1501.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
E. Dayyat, L. D. Serpero, L. Kheirandish-Gozal, J. L. Goldman, A. Snow, R. Bhattacharjee, and D. Gozal
Leukotriene Pathways and In Vitro Adenotonsillar Cell Proliferation in Children With Obstructive Sleep Apnea
Chest, May 1, 2009; 135(5): 1142 - 1149.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
Y. Qiu, J. Zhu, V. Bandi, K. K Guntupalli, and P. K Jeffery
Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma
Thorax, June 1, 2007; 62(6): 475 - 482.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. M. Kelly, J. Chakir, D. Vethanayagam, L.-P. Boulet, M. Laviolette, J. Gauldie, and P. M. O'Byrne
Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge.
Chest, September 1, 2006; 130(3): 741 - 753.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Jiang, Y. Kanaoka, C. Feng, K. Nocka, S. Rao, and J. A. Boyce
Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling.
J. Immunol., September 1, 2006; 177(5): 2755 - 2759.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2005 American Thoracic Society.
  Work-Life